Astellas Pharma Inc (ALPMF) 14.4600 $ALPMF
Osteoarthritis Pain Pipeline Report 2015 - 26 Companies & 46 Drug Profiles
M2 - Fri Jul 10, 3:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w8bmth/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Actavis plc - Addex Therapeutics Ltd - Afferent Pharmaceuticals, Inc. - Akron Molecules AG - Amgen Inc. - Ampio Pharmaceuticals, Inc. - AnaMar AB - Antibe Therapeutics, Inc. - Astellas Pharma Inc. - Boehringer Ingelheim GmbH - Bone Medical Limited - Eli Lilly and Company - Flexion Therapeutics, Inc. - Grunenthal GmbH - iCeutica, Inc. - Iroko Pharmaceuticals, LLC - Nektar Therapeutics - Nuvo Research Inc. - Pfizer Inc. - Phosphagenics Limited - Pozen, Inc. - Purdue Pharma L.P. - Regeneron Pharmaceuticals, Inc. - Rottapharm SpA - Teva Pharmaceutical Industries Limited Drug Profiles - (lidocaine tetracaine) - A-889425 - AAT-008 - ADX-71441 - AF-219 - AKR-202 - AMAP-102 - Ampion - AQU-010 - AS-288640100 - ATB-346 - BI-1026706 - calcitonin - cebranopadol - celecoxib - CGS-125 - CRB-0022 - CRB-0089 - duloxetine hydrochloride DR - ELS-130 - fasinumab - fulranumab - FX-005 - grapiprant - ibuprofen - ibuprofen - LY-2951742 - meloxicam - naproxen sodium - NEO-5024 - NEO-6860 - NKTR-181 - OLT-1177 - onabotulinumtoxin A - oxycodone ER For more information visit http://www.researchandmarkets.com/research/w8...oarthritis
FLXN: 23.74 (+1.31), PFE: 34.36 (+0.50), AMGN: 154.10 (+2.79), AMPE: 2.51 (+0.24), LLY: 88.29 (+0.81), NKTR: 11.40 (+0.22), TEVA: 61.38 (-0.75), ABBV: 69.23 (+1.26), POZN: 10.14 (-0.25), REGN: 526.01 (+16.98)
Kidney Transplantation Pipeline Review, H1 2015 - 20 Companies & 28 Drug Profiles
M2 - Fri Jul 10, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fkfdjl/kidney) has announced the addition of the "Kidney Transplantation - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexion Pharmaceuticals, Inc. - Angion Biomedica Corp. - Astellas Pharma Inc. - Bio-inRen - CSL Limited - Digna Biotech, S.L. - Effimune SAS - GlaxoSmithKline plc - Grifols, S.A. - Hansa Medical AB - Kyowa Hakko Kirin Co., Ltd. - Novartis AG - Onyx Pharmaceuticals, Inc. - Opsona Therapeutics Ltd. - Pharmicell Co., Ltd. - Pharming Group N.V. - Quark Pharmaceuticals, Inc. - Shire Plc - t-cell Europe GmbH - Tolera Therapeutics, Inc. Drug Profiles - albumin (human) - AS-2521780 - ASKP-1240 - BB-3 - belimumab - BRN-1889 - C1 esterase inhibitor (human) - C1 esterase inhibitor (recombinant) - cardiotrophin-1 - carfilzomib - Cell Therapy for Kidney Transplantation - Cell Therapy for Kidney Transplantation - CFZ-533 - eculizumab - EFFI-7H - ETR-002 - FCR-001 - foralumab - FX-06 - IgG-Degrading Enzyme of Streptococcus pyogenes - Immucellgram - Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation and Ischemia Reperfusion Injury - OPN-305 - QPI-1002 - Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation - T-Cell Therapy for Kidney Transplant - TOL-101 - voclosporin For more information visit http://www.researchandmarkets.com/research/fkfdjl/kidney
SHPG: 250.34 (+7.35), ALXN: 192.53 (+4.37), GSK: 42.45 (+0.65), NVS: 103.22 (+3.20)
Overactive Bladder Therapeutics Pipeline Review, H1 2015 - 23 Companies & 32 Drug Profiles
M2 - Thu Jul 09, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gb7727/overactive) has announced the addition of the "Overactive Bladder - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Overactive Bladder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Overactive Bladder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - Allergan, Inc. - Asahi Kasei Pharma Corp. - Astellas Pharma Inc. - Dong-A Socio Group - FemmePharma Global Healthcare, Inc. - Ferring International Center S.A. - Hydra Biosciences, Inc. - Ion Channel Innovations, LLC - Ipsen S.A. - Jeil Pharmaceutical Co., Ltd. - Laboratorios SALVAT S.A. - Lipella Pharmaceuticals, Inc. - Merck & Co., Inc. - Mezzion Pharma Co. Ltd. - MI.TO. Technology S.r.L. - NeuroSearch A/S - Recordati S.p.A. - Sanofi - Takeda Pharmaceutical Company Limited - TARIS BioMedical, Inc. - TheraVida, Inc. - Toray Industries, Inc. Drug Profiles - (mirabegron solifenacin succinate) - abobotulinumtoxin A - ADX-71441 - DA-8010 - FE-999309 - HC-067047 - JLP-1207 - mirabegron ER - NS-19504 - onabotulinumtoxin A liposomal - oxybutynin chloride - oxybutynin hydrochloride - Peptide to Antagonize PACAP Receptor for CNS and Overactive Bladder - pVAX-hSlo - REC-0438 - SAR-244181 - senrebotase - Small Molecule to Agonize GABAB Receptor for Overactive Bladder and Pain - Small Molecule to Antagonize Neurokinin-1 Receptor for Overactive Bladder - Small Molecules to Agonize Beta3-Adrenoceptor for Anxiety, Depression and Overactive Bladder - Small Molecules to Antagonize EP1 Receptor for Overactive Bladder - Small Molecules to Antagonize TRPM8 for Overactive Bladder and Pain - Small Molecules to Antagonize TRPV1 for Overactive Bladder - solifenacin succinate - solifenacin succinate - tacrolimus liposomal - tarafenacin - TD-302 - THVD-201 - THVD-202 - udenafil - vibegron For more information visit http://www.researchandmarkets.com/research/gb7727/overactive
AGN: 312.13 (+8.03), MRK: 57.95 (+0.57)
Chronic Kidney Disease (Chronic Renal Failure) Pipeline Review, H1 2015 - 28 Companies & 42 Drug Profiles
M2 - Thu Jul 09, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/58mtw9/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - AFFiRiS AG - Angion Biomedica Corp. - Astellas Pharma Inc. - Bayer AG - Bio-inRen - Boryung Pharmaceutical Co., Ltd. - Celtic Biotech, Ltd. - Concert Pharmaceuticals, Inc. - Eli Lilly and Company - Evotec AG - Intercept Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Multi Gene Vascular Systems Ltd - Nippon Zoki Pharmaceutical Co., Ltd. - OPKO Health, Inc. - Otsuka Holdings Co., Ltd. - Prolong Pharmaceuticals - ProMetic Life Sciences Inc. - Quark Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - Red Glead Discovery AB - Resverlogix Corp. - Sphaera Pharma Pvt. Ltd. - Stelic Institute & Co. - Toray Industries, Inc. - VBS Pharmaceuticals - Vicore Pharma AB For more information visit http://www.researchandmarkets.com/research/58...nic_kidney
OPK: 16.55 (-0.01), ICPT: 247.71 (+4.45), LLY: 88.29 (+0.81), CNCE: 15.71 (+0.27), XLRN: 30.03 (+0.20)
Emesis (Vomiting) Pipeline Review, H1 2015 - 3 Companies & 5 Drug Profiles
M2 - Thu Jul 09, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2sw7t4/emesis_vomiting) has announced the addition of the "Emesis (Vomiting) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Emesis (Vomiting), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Emesis (Vomiting) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Astellas Pharma Inc. - Daewoong Pharmaceutical Co., Ltd. - Epiomed Therapeutics, Inc. Drug Profiles - Antibody to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - DWJ-1308 - ETI-0001 - ETI-385 - FK-886 For more information visit http://www.researchandmarkets.com/research/2s...s_vomiting
Hairy Cell Leukemia - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qbv58t/hairy_cell) has announced the addition of the "Hairy Cell Leukemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hairy Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hairy Cell Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hairy Cell Leukemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hairy Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hairy Cell Leukemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Astellas Pharma Inc. - AstraZeneca PLC - Biogenomics Limited - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Inbiopro Solutions Pvt. Ltd. - Incyte Corporation - MedImmune, LLC - Plexxikon Inc. For more information visit http://www.researchandmarkets.com/research/qbv58t/hairy_cell
INCY: 108.33 (+0.22), AZN: 66.45 (+1.90), GSK: 42.45 (+0.65)
Peripheral Neuropathic Pain - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9893bq/peripheral) has announced the addition of the "Peripheral Neuropathic Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathic Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - AnaBios Corporation - Astellas Pharma Inc. - Eli Lilly and Company - GW Pharmaceuticals plc - Nektar Therapeutics - Pfizer Inc. - Phosphagenics Limited - Sunovion Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/9893bq/peripheral
PFE: 34.36 (+0.50), LLY: 88.29 (+0.81), NKTR: 11.40 (+0.22)
Astellas Partners with GUMOC to Advance Genitourinary Oncology Research in Canada
CNW Group - Mon Jun 29, 7:00AM CDT
Astellas Pharma Canada, Inc. (Astellas) today announced a new research collaboration with the Genito Urinary Medical Oncologists of Canada (GUMOC) to provide funding and support for genitourinary cancer research in Canada.
Envarsus® XR Demonstrates Differentiated Pharmacokinetic Profile Compared to Twice-Daily Prograf® or Once-Daily Astagraf XL® in Stable Kidney Transplant Patients
PR Newswire - Wed Jun 24, 10:30AM CDT
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced top-line results of the ASTCOFF study, A STeady-state Pharmacokinetic COmparison Of all FK-506 Formulations, demonstrating that once-daily Envarsus® XR (tacrolimus extended-release tablets), an investigational new drug under FDA review for the prevention of organ rejection in adult kidney transplant patients, achieved differentiated pharmacokinetics (PK) when compared to twice-daily tacrolimus (Prograf®) or a once-daily tacrolimus product (Astagraf XL®).
Global Restless Legs Syndrome Market 2015-2019 - Key Players Include Boehringer Ingelheim, GlaxoSmithKline, UCB & XenoPort
M2 - Wed Jun 24, 8:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p7k4v7/global_restless) has announced the addition of the "Global Restless Legs Syndrome Market 2015-2019" report to their offering. The analysts forecast the global RLS market to grow at a CAGR of 11.46% over the period 2014-2019. This report covers the present scenario and the growth prospects of the global RLS market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic, off-label, and branded therapies used for the treatment of RLS. The drugs marketed for RLS such as safinamide by Newron Pharmaceuticals appear to reduce the symptoms by novel mechanisms of action. Safinamide's mechanism of action includes potent, selective, and reversible inhibition of MAO-B, without affecting MAO-A and dopamine uptake, thus enhancing dopaminergic function and inhibiting glutamate release. It reduces the degradation of dopamine, thus showing potential activity in the treatment of RLS. Similarly, Serina's drug SER-214 involves a water-soluble polymer poly (2-alkyloxazoline)-based drug delivery technology. The drug can be connected to the polymer and delivered to target specific receptors. According to the report, the unknown etiology of the disease prevents the introduction of drugs that treat the exact cause of the disease. The currently marketed drugs offer only symptomatic relief. In addition, adverse effects such as nervous system disorders, which include sedation, headache, and dizziness; gastrointestinal disorders such as nausea, dry mouth, and flatulence; psychiatric disorders, including depression and decreased libido; metabolism and nutritional disorders, including weight gain and increased appetite; ear and labyrinth disorders resembling vertigo; and other general disorders such as fatigue, irritability, and peripheral edema are associated with the use of these drugs. This creates unmet needs in the market. Any drug that can provide a complete cure with minimal side effects would experience widespread adoption in the market. Further, the report states that the unknown disease etiology is one of the major challenges for vendors in the market. Key vendors - Boehringer Ingelheim - GlaxoSmithKline - UCB - XenoPort Other prominent vendors - Alexza Pharmaceuticals - Astellas Pharma - Axxonis Pharma - Bayer Healthcare - Impax Pharmaceuticals - Luitpold Pharmaceuticals - Merz Pharmaceuticals - Mundipharma - Newron Pharmaceuticals - Serina Therapeutics - Teva Neuroscience Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Product Profiles - Introduction - Disease Overview - Pipeline Analysis - Commercial Opportunities - Key Brand Analysis - Market Landscape - Market Segmentation by Class of Drugs - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/p7...l_restless
GSK: 42.45 (+0.65), ALXA: 1.19 (+0.25)
Cytokinetics Presents Results From Phase I Studies of CK-2127107
GlobeNewswire - Fri Jun 19, 6:30AM CDT
Cytokinetics (Nasdaq:CYTK) announced today that results from three double-blind, randomized, placebo-controlled Phase I studies of CK-2127107 in healthy volunteers were presented in a poster at the 19 International SMA (Spinal Muscular Atrophy) Researcher Meeting held during the 2015 Annual SMA Conference at the Westin Crown Center in Kansas City, MO. In a pharmacodynamic study that was designed to assess the translation of the mechanism of CK-2127107 to humans, treatment with the fast skeletal muscle activator increased muscle force produced by the tibialis anterior muscle in response to nerve stimulation. Cytokinetics is developing CK-2127107 in collaboration with Astellas Pharma Inc. ("Astellas," Tokyo: 4503).
CYTK: 6.10 (+0.02)
Astellas announces preliminary phase 1/2 safety, tolerability and efficacy data for ASP2215 in patients with relapsed or refractory acute myeloid leukaemia
M2 - Tue Jun 16, 2:49AM CDT
Results from Phase 1/2 trial investigating drug candidate for rare, aggressive blood cancer announced at European Hematology Association Congress; Phase 3 trial planned for late 2015.
Astellas Announces Preliminary Phase 1/2 Safety, Tolerability and Efficacy Data for ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukaemia
PR Newswire Europe - Mon Jun 15, 6:53AM CDT
CHERTSEY, England, June 15, 2015 /PRNewswire/ --
Herpes Zoster (Shingles) Pipeline Review, H1 2015 - 7 Companies & 9 Drug Profiles
M2 - Fri Jun 12, 4:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6mr6fd/herpes_zoster) has announced the addition of the "Herpes Zoster (Shingles) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Zoster (Shingles), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Zoster (Shingles) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Astellas Pharma Inc. - Epiphany Biosciences, Inc. - Foamix Pharmaceuticals Ltd. - GlaxoSmithKline plc - Merck & Co., Inc. - NAL Pharmaceuticals Ltd. - Spider Biotech Drug Profiles - acyclovir - amenamevir - FV-100 - GSK-1437173A - NAL-3221 - NAL-3223 - SB105-A10 - V-212 - valomaciclovir stearate For more information visit http://www.researchandmarkets.com/research/6m...pes_zoster
MRK: 57.95 (+0.57), FOMX: 11.18 (+0.22), GSK: 42.45 (+0.65)
Herpes Simplex Infections Pipeline Review, H1 2015
M2 - Fri Jun 12, 4:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ttlczd/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3-V Biosciences, Inc. - Adamis Pharmaceuticals Corporation - Admedus Ltd - Agenus, Inc. - AiCuris GmbH & Co. KG - AlphaVax, Inc. - Astellas Pharma Inc. - Beech Tree Labs, Inc. - BioApex, s.r.o. - CEL-SCI Corporation - Chimerix, Inc. - Colby Pharmaceutical Company - Epiphany Biosciences, Inc. - Foamix Pharmaceuticals Ltd. - Genocea Biosciences, Inc. - GenVec, Inc. - Immune Design Corp. - Immunovaccine, Inc. - Kala Pharmaceuticals, Inc. - Mymetics Corporation - NanoBio Corporation - NanoViricides, Inc. - NovaBay Pharmaceuticals, Inc. - Onxeo SA - Oryzon Genomics S.A. - Osel Inc. - PaxVax - Peregrine Pharmaceuticals, Inc. - Profectus BioSciences, Inc. - Romark Laboratories, L.C. - Sanofi - Sanofi Pasteur SA - Spider Biotech - Starpharma Holdings Limited - Vaccibody AS For more information visit http://www.researchandmarkets.com/research/tt...es_simplex
IMDZ: 24.04 (+3.00), CVM: 0.67 (+0.04), FOMX: 11.18 (+0.22), ADMP: 4.08 (+0.08), GNCA: 14.39 (+0.15), NNVC: 1.56 (-0.04), CMRX: 46.90 (+1.08)
Cytokinetics Announces Poster Presentation on CK-2127107 at the 19th International SMA Researcher Meeting
GlobeNewswire - Thu Jun 11, 3:00PM CDT
Cytokinetics, (Nasdaq:CYTK) announced today that a poster presentation on the company's fast skeletal muscle activator, CK-2127107, will be presented at the 19 International SMA Researcher Meeting to be held during the 2015 Annual SMA Conference June 18-20, 2015 at the Westin Crown Center in Kansas City, MO. Cytokinetics is developing CK-2127107 in collaboration with Astellas Pharma Inc. ("Astellas," Tokyo: 4503).
CYTK: 6.10 (+0.02)
Transitional Cell Cancer (Urothelial Cell Cancer) Pipeline Review, H1 2015 - 17 Companies & 22 Drug Profiles
M2 - Thu Jun 11, 6:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jnvpb5/transitional_cell) has announced the addition of the "Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Transitional Cell Cancer (Urothelial Cell Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Cancer (Urothelial Cell Cancer) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Altor BioScience Corporation - Astellas Pharma Inc. - AstraZeneca PLC - Boston Biomedical, Inc. - Corcept Therapeutics Incorporated - Eli Lilly and Company - Exelixis, Inc. - GlaxoSmithKline plc - Innate Therapeutics Limited - Merck & Co., Inc. - Merck KGaA - Mirati Therapeutics Inc. - Novartis AG - Pfizer Inc. - Sanofi - Sumitomo Dainippon Pharma Co., Ltd. - Teva Pharmaceutical Industries Limited Drug Profiles - ACP-196 - AGS-15E - ALT-801 - amrubicin hydrochloride - ASG-15ME - avelumab - AZD-4547 - BBI-503 - buparlisib hydrochloride - cabazitaxel - cabozantinib s-malate - CEP-11981 - enfortumab vedotin - mifepristone - MIS-416 - mocetinostat - palbociclib - pembrolizumab - ramucirumab - SAR-408701 - SNX-5422 - trametinib dimethyl sulfoxide For more information visit http://www.researchandmarkets.com/research/jn...ional_cell
PFE: 34.36 (+0.50), MRK: 57.95 (+0.57), AZN: 66.45 (+1.90), TEVA: 61.38 (-0.75), LLY: 88.29 (+0.81), MRTX: 31.67 (+0.81), GSK: 42.45 (+0.65), CORT: 5.88 (+0.14), NVS: 103.22 (+3.20), EXEL: 3.68 (+0.25)
Varicella Zoster (HHV-3) Infections - Pipeline Review, H1 2015
M2 - Thu Jun 11, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/779336/varicella_zoster) has announced the addition of the "Varicella Zoster (HHV-3) Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Varicella Zoster (HHV-3) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Varicella Zoster (HHV-3) Infections and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Astellas Pharma - Beijing Minhai Biotechnology - Beijing Tiantan Biological Products - China National Pharmaceutical - Chongqing Zhifei Biological Products - Epiphany Biosciences - Foamix Pharmaceuticals - GlaxoSmithKline - Green Cross - Merck & Co. - NAL Pharmaceuticals - Sinovac Biotech - SK Chemicals - Spider Biotech For more information visit http://www.researchandmarkets.com/research/77...lla_zoster
MRK: 57.95 (+0.57), FOMX: 11.18 (+0.22), GSK: 42.45 (+0.65), SVA: 5.26 (+0.02)
T-Cell Leukemia Pipeline Review, H1 2015 - 14 Companies & 20 Drug Profiles
M2 - Thu Jun 11, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2b68lm/tcell_leukemia) has announced the addition of the "T-Cell Leukemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Applied Immune Technologies Ltd - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - iDD biotech SAS - Kyowa Hakko Kirin Co., Ltd. - MediGene AG - Nippon Kayaku Co., Ltd. - Pfizer Inc. - Pharmacyclics, Inc. - Sanofi - Stemline Therapeutics, Inc. - Theravectys S.A. - Tolero Pharmaceuticals, Inc. Drug Profiles - AGS-67E - alemtuzumab - Antibody to Inhibit HLA-A2 for Neurology, Infectious Diseases and T-Cell Leukemia - BMS-906024 - Cell Therapy to Target CD38 for cancer - IDD-003 - INA-01 - lenalidomide - MMIG-202 - mogamulizumab - Monoclonal Antibodies to Antagonize TCR for Leukemia and Autoimmune Disease - Monoclonal Antibody to Target CCR9 for T Lymphoblastic Leukemia - NK-314 - Oncolytic Virus to Target Glycoprotein gp160 for T-cell Leukemia - PCI-34051 - PF-03084014 - SL-101 - Synthetic Peptide for Oncology and Male health - THV-02 - TP-0903 For more information visit http://www.researchandmarkets.com/research/2b...l_leukemia
PCYC: 261.25 (+1.70), PFE: 34.36 (+0.50), BMY: 69.27 (+1.38), STML: 11.86 (+0.03), CELGZ: 2.15 (+0.14)
Postherpetic Neuralgia - Pipeline Review, H1 2015
M2 - Thu Jun 11, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hg24hw/postherpetic) has announced the addition of the "Postherpetic Neuralgia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Postherpetic Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - Aestus Therapeutics - Allergan - Arcion Therapeutics - Astellas Pharma - Daewoong Pharmaceutical - Daiichi Sankyo - Immune Pharmaceuticals - Intellipharmaceutics International - Merck & Co. - NeurAxon - Nuvo Research - Pfizer - Phosphagenics - Purdue Pharma - Relmada Therapeutics - Scilex Pharmaceuticals - Spinifex Pharmaceuticals - Teva Pharmaceutical Industries - Winston Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/hg...stherpetic
AGN: 312.13 (+8.03), IPCI: 3.48 (+0.03), MRK: 57.95 (+0.57), TEVA: 61.38 (-0.75), IMNP: 1.88 (+0.04)
Osteoarthritis Pain Pipeline Report 2015 - 26 Companies & 46 Drug Profiles
M2 - Fri Jul 10, 3:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w8bmth/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Actavis plc - Addex Therapeutics Ltd - Afferent Pharmaceuticals, Inc. - Akron Molecules AG - Amgen Inc. - Ampio Pharmaceuticals, Inc. - AnaMar AB - Antibe Therapeutics, Inc. - Astellas Pharma Inc. - Boehringer Ingelheim GmbH - Bone Medical Limited - Eli Lilly and Company - Flexion Therapeutics, Inc. - Grunenthal GmbH - iCeutica, Inc. - Iroko Pharmaceuticals, LLC - Nektar Therapeutics - Nuvo Research Inc. - Pfizer Inc. - Phosphagenics Limited - Pozen, Inc. - Purdue Pharma L.P. - Regeneron Pharmaceuticals, Inc. - Rottapharm SpA - Teva Pharmaceutical Industries Limited Drug Profiles - (lidocaine tetracaine) - A-889425 - AAT-008 - ADX-71441 - AF-219 - AKR-202 - AMAP-102 - Ampion - AQU-010 - AS-288640100 - ATB-346 - BI-1026706 - calcitonin - cebranopadol - celecoxib - CGS-125 - CRB-0022 - CRB-0089 - duloxetine hydrochloride DR - ELS-130 - fasinumab - fulranumab - FX-005 - grapiprant - ibuprofen - ibuprofen - LY-2951742 - meloxicam - naproxen sodium - NEO-5024 - NEO-6860 - NKTR-181 - OLT-1177 - onabotulinumtoxin A - oxycodone ER For more information visit http://www.researchandmarkets.com/research/w8...oarthritis
FLXN: 23.74 (+1.31), PFE: 34.36 (+0.50), AMGN: 154.10 (+2.79), AMPE: 2.51 (+0.24), LLY: 88.29 (+0.81), NKTR: 11.40 (+0.22), TEVA: 61.38 (-0.75), ABBV: 69.23 (+1.26), POZN: 10.14 (-0.25), REGN: 526.01 (+16.98)
Kidney Transplantation Pipeline Review, H1 2015 - 20 Companies & 28 Drug Profiles
M2 - Fri Jul 10, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fkfdjl/kidney) has announced the addition of the "Kidney Transplantation - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexion Pharmaceuticals, Inc. - Angion Biomedica Corp. - Astellas Pharma Inc. - Bio-inRen - CSL Limited - Digna Biotech, S.L. - Effimune SAS - GlaxoSmithKline plc - Grifols, S.A. - Hansa Medical AB - Kyowa Hakko Kirin Co., Ltd. - Novartis AG - Onyx Pharmaceuticals, Inc. - Opsona Therapeutics Ltd. - Pharmicell Co., Ltd. - Pharming Group N.V. - Quark Pharmaceuticals, Inc. - Shire Plc - t-cell Europe GmbH - Tolera Therapeutics, Inc. Drug Profiles - albumin (human) - AS-2521780 - ASKP-1240 - BB-3 - belimumab - BRN-1889 - C1 esterase inhibitor (human) - C1 esterase inhibitor (recombinant) - cardiotrophin-1 - carfilzomib - Cell Therapy for Kidney Transplantation - Cell Therapy for Kidney Transplantation - CFZ-533 - eculizumab - EFFI-7H - ETR-002 - FCR-001 - foralumab - FX-06 - IgG-Degrading Enzyme of Streptococcus pyogenes - Immucellgram - Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation and Ischemia Reperfusion Injury - OPN-305 - QPI-1002 - Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation - T-Cell Therapy for Kidney Transplant - TOL-101 - voclosporin For more information visit http://www.researchandmarkets.com/research/fkfdjl/kidney
SHPG: 250.34 (+7.35), ALXN: 192.53 (+4.37), GSK: 42.45 (+0.65), NVS: 103.22 (+3.20)
Overactive Bladder Therapeutics Pipeline Review, H1 2015 - 23 Companies & 32 Drug Profiles
M2 - Thu Jul 09, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gb7727/overactive) has announced the addition of the "Overactive Bladder - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Overactive Bladder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Overactive Bladder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - Allergan, Inc. - Asahi Kasei Pharma Corp. - Astellas Pharma Inc. - Dong-A Socio Group - FemmePharma Global Healthcare, Inc. - Ferring International Center S.A. - Hydra Biosciences, Inc. - Ion Channel Innovations, LLC - Ipsen S.A. - Jeil Pharmaceutical Co., Ltd. - Laboratorios SALVAT S.A. - Lipella Pharmaceuticals, Inc. - Merck & Co., Inc. - Mezzion Pharma Co. Ltd. - MI.TO. Technology S.r.L. - NeuroSearch A/S - Recordati S.p.A. - Sanofi - Takeda Pharmaceutical Company Limited - TARIS BioMedical, Inc. - TheraVida, Inc. - Toray Industries, Inc. Drug Profiles - (mirabegron solifenacin succinate) - abobotulinumtoxin A - ADX-71441 - DA-8010 - FE-999309 - HC-067047 - JLP-1207 - mirabegron ER - NS-19504 - onabotulinumtoxin A liposomal - oxybutynin chloride - oxybutynin hydrochloride - Peptide to Antagonize PACAP Receptor for CNS and Overactive Bladder - pVAX-hSlo - REC-0438 - SAR-244181 - senrebotase - Small Molecule to Agonize GABAB Receptor for Overactive Bladder and Pain - Small Molecule to Antagonize Neurokinin-1 Receptor for Overactive Bladder - Small Molecules to Agonize Beta3-Adrenoceptor for Anxiety, Depression and Overactive Bladder - Small Molecules to Antagonize EP1 Receptor for Overactive Bladder - Small Molecules to Antagonize TRPM8 for Overactive Bladder and Pain - Small Molecules to Antagonize TRPV1 for Overactive Bladder - solifenacin succinate - solifenacin succinate - tacrolimus liposomal - tarafenacin - TD-302 - THVD-201 - THVD-202 - udenafil - vibegron For more information visit http://www.researchandmarkets.com/research/gb7727/overactive
AGN: 312.13 (+8.03), MRK: 57.95 (+0.57)
Chronic Kidney Disease (Chronic Renal Failure) Pipeline Review, H1 2015 - 28 Companies & 42 Drug Profiles
M2 - Thu Jul 09, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/58mtw9/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - AFFiRiS AG - Angion Biomedica Corp. - Astellas Pharma Inc. - Bayer AG - Bio-inRen - Boryung Pharmaceutical Co., Ltd. - Celtic Biotech, Ltd. - Concert Pharmaceuticals, Inc. - Eli Lilly and Company - Evotec AG - Intercept Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Multi Gene Vascular Systems Ltd - Nippon Zoki Pharmaceutical Co., Ltd. - OPKO Health, Inc. - Otsuka Holdings Co., Ltd. - Prolong Pharmaceuticals - ProMetic Life Sciences Inc. - Quark Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - Red Glead Discovery AB - Resverlogix Corp. - Sphaera Pharma Pvt. Ltd. - Stelic Institute & Co. - Toray Industries, Inc. - VBS Pharmaceuticals - Vicore Pharma AB For more information visit http://www.researchandmarkets.com/research/58...nic_kidney
OPK: 16.55 (-0.01), ICPT: 247.71 (+4.45), LLY: 88.29 (+0.81), CNCE: 15.71 (+0.27), XLRN: 30.03 (+0.20)
Emesis (Vomiting) Pipeline Review, H1 2015 - 3 Companies & 5 Drug Profiles
M2 - Thu Jul 09, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2sw7t4/emesis_vomiting) has announced the addition of the "Emesis (Vomiting) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Emesis (Vomiting), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Emesis (Vomiting) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Astellas Pharma Inc. - Daewoong Pharmaceutical Co., Ltd. - Epiomed Therapeutics, Inc. Drug Profiles - Antibody to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - DWJ-1308 - ETI-0001 - ETI-385 - FK-886 For more information visit http://www.researchandmarkets.com/research/2s...s_vomiting
Hairy Cell Leukemia - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qbv58t/hairy_cell) has announced the addition of the "Hairy Cell Leukemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hairy Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hairy Cell Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hairy Cell Leukemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hairy Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hairy Cell Leukemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Astellas Pharma Inc. - AstraZeneca PLC - Biogenomics Limited - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Inbiopro Solutions Pvt. Ltd. - Incyte Corporation - MedImmune, LLC - Plexxikon Inc. For more information visit http://www.researchandmarkets.com/research/qbv58t/hairy_cell
INCY: 108.33 (+0.22), AZN: 66.45 (+1.90), GSK: 42.45 (+0.65)
Peripheral Neuropathic Pain - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9893bq/peripheral) has announced the addition of the "Peripheral Neuropathic Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathic Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - AnaBios Corporation - Astellas Pharma Inc. - Eli Lilly and Company - GW Pharmaceuticals plc - Nektar Therapeutics - Pfizer Inc. - Phosphagenics Limited - Sunovion Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/9893bq/peripheral
PFE: 34.36 (+0.50), LLY: 88.29 (+0.81), NKTR: 11.40 (+0.22)
Astellas Partners with GUMOC to Advance Genitourinary Oncology Research in Canada
CNW Group - Mon Jun 29, 7:00AM CDT
Astellas Pharma Canada, Inc. (Astellas) today announced a new research collaboration with the Genito Urinary Medical Oncologists of Canada (GUMOC) to provide funding and support for genitourinary cancer research in Canada.
Envarsus® XR Demonstrates Differentiated Pharmacokinetic Profile Compared to Twice-Daily Prograf® or Once-Daily Astagraf XL® in Stable Kidney Transplant Patients
PR Newswire - Wed Jun 24, 10:30AM CDT
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced top-line results of the ASTCOFF study, A STeady-state Pharmacokinetic COmparison Of all FK-506 Formulations, demonstrating that once-daily Envarsus® XR (tacrolimus extended-release tablets), an investigational new drug under FDA review for the prevention of organ rejection in adult kidney transplant patients, achieved differentiated pharmacokinetics (PK) when compared to twice-daily tacrolimus (Prograf®) or a once-daily tacrolimus product (Astagraf XL®).
Global Restless Legs Syndrome Market 2015-2019 - Key Players Include Boehringer Ingelheim, GlaxoSmithKline, UCB & XenoPort
M2 - Wed Jun 24, 8:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p7k4v7/global_restless) has announced the addition of the "Global Restless Legs Syndrome Market 2015-2019" report to their offering. The analysts forecast the global RLS market to grow at a CAGR of 11.46% over the period 2014-2019. This report covers the present scenario and the growth prospects of the global RLS market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic, off-label, and branded therapies used for the treatment of RLS. The drugs marketed for RLS such as safinamide by Newron Pharmaceuticals appear to reduce the symptoms by novel mechanisms of action. Safinamide's mechanism of action includes potent, selective, and reversible inhibition of MAO-B, without affecting MAO-A and dopamine uptake, thus enhancing dopaminergic function and inhibiting glutamate release. It reduces the degradation of dopamine, thus showing potential activity in the treatment of RLS. Similarly, Serina's drug SER-214 involves a water-soluble polymer poly (2-alkyloxazoline)-based drug delivery technology. The drug can be connected to the polymer and delivered to target specific receptors. According to the report, the unknown etiology of the disease prevents the introduction of drugs that treat the exact cause of the disease. The currently marketed drugs offer only symptomatic relief. In addition, adverse effects such as nervous system disorders, which include sedation, headache, and dizziness; gastrointestinal disorders such as nausea, dry mouth, and flatulence; psychiatric disorders, including depression and decreased libido; metabolism and nutritional disorders, including weight gain and increased appetite; ear and labyrinth disorders resembling vertigo; and other general disorders such as fatigue, irritability, and peripheral edema are associated with the use of these drugs. This creates unmet needs in the market. Any drug that can provide a complete cure with minimal side effects would experience widespread adoption in the market. Further, the report states that the unknown disease etiology is one of the major challenges for vendors in the market. Key vendors - Boehringer Ingelheim - GlaxoSmithKline - UCB - XenoPort Other prominent vendors - Alexza Pharmaceuticals - Astellas Pharma - Axxonis Pharma - Bayer Healthcare - Impax Pharmaceuticals - Luitpold Pharmaceuticals - Merz Pharmaceuticals - Mundipharma - Newron Pharmaceuticals - Serina Therapeutics - Teva Neuroscience Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Product Profiles - Introduction - Disease Overview - Pipeline Analysis - Commercial Opportunities - Key Brand Analysis - Market Landscape - Market Segmentation by Class of Drugs - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/p7...l_restless
GSK: 42.45 (+0.65), ALXA: 1.19 (+0.25)
Cytokinetics Presents Results From Phase I Studies of CK-2127107
GlobeNewswire - Fri Jun 19, 6:30AM CDT
Cytokinetics (Nasdaq:CYTK) announced today that results from three double-blind, randomized, placebo-controlled Phase I studies of CK-2127107 in healthy volunteers were presented in a poster at the 19 International SMA (Spinal Muscular Atrophy) Researcher Meeting held during the 2015 Annual SMA Conference at the Westin Crown Center in Kansas City, MO. In a pharmacodynamic study that was designed to assess the translation of the mechanism of CK-2127107 to humans, treatment with the fast skeletal muscle activator increased muscle force produced by the tibialis anterior muscle in response to nerve stimulation. Cytokinetics is developing CK-2127107 in collaboration with Astellas Pharma Inc. ("Astellas," Tokyo: 4503).
CYTK: 6.10 (+0.02)
Astellas announces preliminary phase 1/2 safety, tolerability and efficacy data for ASP2215 in patients with relapsed or refractory acute myeloid leukaemia
M2 - Tue Jun 16, 2:49AM CDT
Results from Phase 1/2 trial investigating drug candidate for rare, aggressive blood cancer announced at European Hematology Association Congress; Phase 3 trial planned for late 2015.
Astellas Announces Preliminary Phase 1/2 Safety, Tolerability and Efficacy Data for ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukaemia
PR Newswire Europe - Mon Jun 15, 6:53AM CDT
CHERTSEY, England, June 15, 2015 /PRNewswire/ --
Herpes Zoster (Shingles) Pipeline Review, H1 2015 - 7 Companies & 9 Drug Profiles
M2 - Fri Jun 12, 4:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6mr6fd/herpes_zoster) has announced the addition of the "Herpes Zoster (Shingles) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Zoster (Shingles), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Zoster (Shingles) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Astellas Pharma Inc. - Epiphany Biosciences, Inc. - Foamix Pharmaceuticals Ltd. - GlaxoSmithKline plc - Merck & Co., Inc. - NAL Pharmaceuticals Ltd. - Spider Biotech Drug Profiles - acyclovir - amenamevir - FV-100 - GSK-1437173A - NAL-3221 - NAL-3223 - SB105-A10 - V-212 - valomaciclovir stearate For more information visit http://www.researchandmarkets.com/research/6m...pes_zoster
MRK: 57.95 (+0.57), FOMX: 11.18 (+0.22), GSK: 42.45 (+0.65)
Herpes Simplex Infections Pipeline Review, H1 2015
M2 - Fri Jun 12, 4:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ttlczd/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3-V Biosciences, Inc. - Adamis Pharmaceuticals Corporation - Admedus Ltd - Agenus, Inc. - AiCuris GmbH & Co. KG - AlphaVax, Inc. - Astellas Pharma Inc. - Beech Tree Labs, Inc. - BioApex, s.r.o. - CEL-SCI Corporation - Chimerix, Inc. - Colby Pharmaceutical Company - Epiphany Biosciences, Inc. - Foamix Pharmaceuticals Ltd. - Genocea Biosciences, Inc. - GenVec, Inc. - Immune Design Corp. - Immunovaccine, Inc. - Kala Pharmaceuticals, Inc. - Mymetics Corporation - NanoBio Corporation - NanoViricides, Inc. - NovaBay Pharmaceuticals, Inc. - Onxeo SA - Oryzon Genomics S.A. - Osel Inc. - PaxVax - Peregrine Pharmaceuticals, Inc. - Profectus BioSciences, Inc. - Romark Laboratories, L.C. - Sanofi - Sanofi Pasteur SA - Spider Biotech - Starpharma Holdings Limited - Vaccibody AS For more information visit http://www.researchandmarkets.com/research/tt...es_simplex
IMDZ: 24.04 (+3.00), CVM: 0.67 (+0.04), FOMX: 11.18 (+0.22), ADMP: 4.08 (+0.08), GNCA: 14.39 (+0.15), NNVC: 1.56 (-0.04), CMRX: 46.90 (+1.08)
Cytokinetics Announces Poster Presentation on CK-2127107 at the 19th International SMA Researcher Meeting
GlobeNewswire - Thu Jun 11, 3:00PM CDT
Cytokinetics, (Nasdaq:CYTK) announced today that a poster presentation on the company's fast skeletal muscle activator, CK-2127107, will be presented at the 19 International SMA Researcher Meeting to be held during the 2015 Annual SMA Conference June 18-20, 2015 at the Westin Crown Center in Kansas City, MO. Cytokinetics is developing CK-2127107 in collaboration with Astellas Pharma Inc. ("Astellas," Tokyo: 4503).
CYTK: 6.10 (+0.02)
Transitional Cell Cancer (Urothelial Cell Cancer) Pipeline Review, H1 2015 - 17 Companies & 22 Drug Profiles
M2 - Thu Jun 11, 6:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jnvpb5/transitional_cell) has announced the addition of the "Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Transitional Cell Cancer (Urothelial Cell Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Cancer (Urothelial Cell Cancer) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Altor BioScience Corporation - Astellas Pharma Inc. - AstraZeneca PLC - Boston Biomedical, Inc. - Corcept Therapeutics Incorporated - Eli Lilly and Company - Exelixis, Inc. - GlaxoSmithKline plc - Innate Therapeutics Limited - Merck & Co., Inc. - Merck KGaA - Mirati Therapeutics Inc. - Novartis AG - Pfizer Inc. - Sanofi - Sumitomo Dainippon Pharma Co., Ltd. - Teva Pharmaceutical Industries Limited Drug Profiles - ACP-196 - AGS-15E - ALT-801 - amrubicin hydrochloride - ASG-15ME - avelumab - AZD-4547 - BBI-503 - buparlisib hydrochloride - cabazitaxel - cabozantinib s-malate - CEP-11981 - enfortumab vedotin - mifepristone - MIS-416 - mocetinostat - palbociclib - pembrolizumab - ramucirumab - SAR-408701 - SNX-5422 - trametinib dimethyl sulfoxide For more information visit http://www.researchandmarkets.com/research/jn...ional_cell
PFE: 34.36 (+0.50), MRK: 57.95 (+0.57), AZN: 66.45 (+1.90), TEVA: 61.38 (-0.75), LLY: 88.29 (+0.81), MRTX: 31.67 (+0.81), GSK: 42.45 (+0.65), CORT: 5.88 (+0.14), NVS: 103.22 (+3.20), EXEL: 3.68 (+0.25)
Varicella Zoster (HHV-3) Infections - Pipeline Review, H1 2015
M2 - Thu Jun 11, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/779336/varicella_zoster) has announced the addition of the "Varicella Zoster (HHV-3) Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Varicella Zoster (HHV-3) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Varicella Zoster (HHV-3) Infections and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Astellas Pharma - Beijing Minhai Biotechnology - Beijing Tiantan Biological Products - China National Pharmaceutical - Chongqing Zhifei Biological Products - Epiphany Biosciences - Foamix Pharmaceuticals - GlaxoSmithKline - Green Cross - Merck & Co. - NAL Pharmaceuticals - Sinovac Biotech - SK Chemicals - Spider Biotech For more information visit http://www.researchandmarkets.com/research/77...lla_zoster
MRK: 57.95 (+0.57), FOMX: 11.18 (+0.22), GSK: 42.45 (+0.65), SVA: 5.26 (+0.02)
T-Cell Leukemia Pipeline Review, H1 2015 - 14 Companies & 20 Drug Profiles
M2 - Thu Jun 11, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2b68lm/tcell_leukemia) has announced the addition of the "T-Cell Leukemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Applied Immune Technologies Ltd - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - iDD biotech SAS - Kyowa Hakko Kirin Co., Ltd. - MediGene AG - Nippon Kayaku Co., Ltd. - Pfizer Inc. - Pharmacyclics, Inc. - Sanofi - Stemline Therapeutics, Inc. - Theravectys S.A. - Tolero Pharmaceuticals, Inc. Drug Profiles - AGS-67E - alemtuzumab - Antibody to Inhibit HLA-A2 for Neurology, Infectious Diseases and T-Cell Leukemia - BMS-906024 - Cell Therapy to Target CD38 for cancer - IDD-003 - INA-01 - lenalidomide - MMIG-202 - mogamulizumab - Monoclonal Antibodies to Antagonize TCR for Leukemia and Autoimmune Disease - Monoclonal Antibody to Target CCR9 for T Lymphoblastic Leukemia - NK-314 - Oncolytic Virus to Target Glycoprotein gp160 for T-cell Leukemia - PCI-34051 - PF-03084014 - SL-101 - Synthetic Peptide for Oncology and Male health - THV-02 - TP-0903 For more information visit http://www.researchandmarkets.com/research/2b...l_leukemia
PCYC: 261.25 (+1.70), PFE: 34.36 (+0.50), BMY: 69.27 (+1.38), STML: 11.86 (+0.03), CELGZ: 2.15 (+0.14)
Postherpetic Neuralgia - Pipeline Review, H1 2015
M2 - Thu Jun 11, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hg24hw/postherpetic) has announced the addition of the "Postherpetic Neuralgia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Postherpetic Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - Aestus Therapeutics - Allergan - Arcion Therapeutics - Astellas Pharma - Daewoong Pharmaceutical - Daiichi Sankyo - Immune Pharmaceuticals - Intellipharmaceutics International - Merck & Co. - NeurAxon - Nuvo Research - Pfizer - Phosphagenics - Purdue Pharma - Relmada Therapeutics - Scilex Pharmaceuticals - Spinifex Pharmaceuticals - Teva Pharmaceutical Industries - Winston Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/hg...stherpetic
AGN: 312.13 (+8.03), IPCI: 3.48 (+0.03), MRK: 57.95 (+0.57), TEVA: 61.38 (-0.75), IMNP: 1.88 (+0.04)
